Safety of intracerebroventricular copper histidine in adult rats
| Autor: | Stephen G. Kaler, Jose A. Centeno, Kristen E. Lem, Simina Lal, Martin J. Lizak, Sarah C. Godwin, Olga Tjurmina, Po-Ching Liu, Lauren R. Brinster |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Maximum Tolerated Dose Endocrinology Diabetes and Metabolism ATPase Central nervous system ATP7A Brain Edema Biochemistry Article Rats Sprague-Dawley Endocrinology Internal medicine Genetics medicine Organometallic Compounds Distribution (pharmacology) Animals Histidine Menkes Kinky Hair Syndrome Molecular Biology Injections Intraventricular medicine.diagnostic_test biology Dose-Response Relationship Drug Chemistry Brain Magnetic resonance imaging medicine.disease Magnetic Resonance Imaging Rats Radiography medicine.anatomical_structure Toxicity biology.protein Menkes disease |
| Zdroj: | Molecular genetics and metabolism. 91(1) |
| ISSN: | 1096-7192 |
| Popis: | Classical Menkes disease is an X-linked recessive neurodegenerative disorder caused by mutations in a P-type ATPase (ATP7A) that normally delivers copper to the developing central nervous system. Infants with large deletions, or other mutations in ATP7A that incapacitate copper transport to the brain, show poor clinical outcomes and subnormal brain copper despite early subcutaneous copper histidine (CuHis) injections. These findings suggest a need for direct central nervous system approaches in such patients. To begin to evaluate an aggressive but potentially useful new strategy for metabolic improvement of this disorder, we studied the acute and chronic effects of CuHis administered by intracerebroventricular (ICV) injection in healthy adult rats. Magnetic resonance imaging (MRI) after ICV CuHis showed diffuse T1-signal enhancement, indicating wide brain distribution of copper after ICV administration, and implying the utility of this paramagnetic metal as a MRI contrast agent. The maximum tolerated dose (MTD) of CuHis, defined as the highest dose that did not induce overt toxicity, growth retardation, or reduce lifespan, was 0.5 mcg. Animals receiving multiple infusions of this MTD showed increased brain copper concentrations, but no significant differences in activity, behavior, and somatic growth, or brain histology compared to saline-injected controls. Based on estimates of the brain copper deficit in Menkes disease patients, CuHis doses 10-fold lower than the MTD found in this study may restore proper brain copper concentration. Our results suggest that ICV CuHis administration have potential as a novel treatment approach in Menkes disease infants with severe mutations. Future trials of direct CNS copper administration in mouse models of Menkes disease will be informative. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect